Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

NCT05544968 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Disease
CD30-Positive Diffuse Large B-Cell Lymphoma
CD30+ Anaplastic Large Cell Lymphoma
CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma
CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma
Leukemia
Lymphoma

Interventions

DRUG: anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
DRUG: GM-CSF

Sponsor

Medical College of Wisconsin